Compare iShares Core MSCI EAFE ETF (IEFA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs GeneDx Holdings Corp — how do they compare? iShares Core MSCI EAFE ETF trades at $96.52 (market cap $189.19B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 93.7× GeneDx Holdings Corp's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 40 Days and GeneDx Holdings Corp for 19 Days on average.
| IEFA | WGS | |
|---|---|---|
Market Cap | $189.19B | $2.02B |
Volume | 8,441,787 | 734,640 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $167.51 |
52-Week Low | $85.06 | $34.51 |
Typical Hold Time | 40 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $95.87, down 0.34% on the day, with a bearish technical signal driven by moving averages and oscillators. The fund provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower costs relative to some peers, though it has underperformed others on a total return basis over the past year.
The outlook for IEFA is mixed, offering diversification benefits and income through dividends but facing headwinds from weaker relative performance and bearish technical momentum. Key risks include concentration in developed markets, which may lag during global growth shifts, and expense ratio competition. Analyst sentiment is cautious due to recent underperformance versus broader global funds.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
